The Restoring Insulin Secretion (RISE) study was initiated to evaluate interventions to slow or reverse the progression of β-cell failure in type 2 diabetes (T2D). To design the RISE study, we undertook an evaluation of methods for measurement of β-cell function and changes in β-cell function in response to interventions. In the present paper, we review approaches for measurement of β-cell function, focusing on methodologic and feasibility considerations. Methodologic considerations included: (1) the utility of each technique for evaluating key aspects of β-cell function (first-and second-phase insulin secretion, maximum insulin secretion, glucose sensitivity, incretin effects) and (2) tactics for incorporating a measurement of insulin sensitivity in order to adjust insulin secretion measures for insulin sensitivity appropriately. Of particular concern were the capacity to measure β-cell function accurately in those with poor function, as is seen in established T2D, and the capacity of each method for demonstrating treatmentinduced changes in β-cell function. Feasibility considerations included: staff burden, including time and required methodological expertise; participant burden, including time and number of study visits; and ease of standardizing methods across a multicentre consortium. After this evaluation, we selected a 2-day measurement procedure, combining a 3-hour 75-g oral glucose tolerance test and a 2-stage hyperglycaemic clamp procedure, augmented with arginine.
| INTRODUCTION
The study of progressive metabolic dysfunction in prediabetes and type 2 diabetes (T2D) has focused on the pancreatic islet β cell. 1 Crosssectional studies in adult and adolescent populations have shown inferior β-cell function in individuals with impaired glucose tolerance (IGT) and even poorer function in those with T2D. [2] [3] [4] [5] Longitudinal assessments to-date demonstrate progressive worsening of β-cell function among individuals with genetic and metabolic risk factors for T2D, and in patients with increasing hyperglycaemia. [6] [7] [8] Methodologies for measuring β-cell function range in complexity from fasting measures to protocols involving intravenous infusion of multiple stimulators of insulin release. [9] [10] [11] [12] [13] [14] [15] [16] Each method has strengths and weaknesses, and selection of the optimum approach must not only reflect pertinent physiology, but also factors such as cost and participant burden.
The Restoring Insulin Secretion (RISE) study was designed to test interventions to slow or reverse the progression of β-cell failure in individuals at high risk of T2D, or with recent-onset T2D. 17 In the present paper, we review the available techniques for measurement of β-cell function, focusing on the methodological and feasibility considerations that informed the selection of approaches used in the RISE study.
| PHYSIOLOGICAL CONSIDERATIONS FOR THE MEASUREMENT OF β-CELL FUNCTION
β-cell function can be defined as the ability of pancreatic β cells to produce, store and release insulin in concentrations sufficient to maintain euglycaemia. Under normal physiological conditions, circulating insulin concentrations are reciprocally related to insulin sensitivity, expressed as the body's capacity for glucose disposal and ability to suppress hepatic glucose production in response to insulin. 10 When insulin sensitivity declines, the appropriate physiological response is for insulin secretion to increase in a compensatory manner. The calculated line linking these factors, which exhibit a square hyperbolic relationship, is commonly expressed as the "disposition index" (DI; insulin sensitivity * first-phase insulin secretion [ Figure 1 ]). 10, 14 The need to incorporate a measurement of insulin sensitivity into assessments of β-cell responses is widely accepted. With this in mind we will briefly review alternatives for measuring insulin sensitivity before turning to methods for assessing β-cell responses.
| MEASURING INSULIN SENSITIVITY
To adjust the β-cell reponse appropriately for the prevailing insulin sensitivity, a concurrent measure of insulin sensitivity is required.
Robust discussions of different approaches to measuring insulin sensitivity have been previously published. [18] [19] [20] Below follows a brief exposition of the available methods, with a focus on the technical limitations and participant burden.
| Hyperinsulinaemic-euglycaemic clamp
The hyperinsulinaemic-euglycaemic clamp technique allows measurement of whole-body and tissue sensitivity to a steady-state concentration of insulin while the plasma glucose concentration is held constant (clamped), generally at physiologically normal (euglycaemic) levels.
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FIGURE 1
The hyperbolic relationship between insulin sensitivity (SI) and the first-phase (acute) insulin response to glucose (AIRglucose) (A) and the maximum acute insulin response to arginine (AIRmax) (B), in a cohort of healthy individuals. The solid line depicts the best-fit relationship (50th percentile), while the broken lines represent the 5th, 25th, 75th, and 95th percentiles. A reduction in insulin sensitivity, as measured by a decrease in Si, results in a compensatory reciprocal and proportionate increase in glucose-stimulated insulin secretion and an increase in maximum acute insulin response to arginine, the latter a measure of β-cell secretory capacity. (Copyright 1993, American Diabetes Association. From Reference 10. Reprinted with permission from the American Diabetes Association)
Performing the procedure in the euglycaemic state obviates the need to correct for the impact of hyperglycaemia on glucose disposal. This method produces measures of insulin-stimulated glucose disposal (M), and insulin sensitivity (M/I, where I denotes steady-state plasma insulin concentration). Because this technique imposes plasma insulin and plasma glucose concentrations at defined experimental levels, independent of insulin production or release, it provides reliable measurements of insulin sensitivity in subjects across the full range of β-cell function.
The limitations of this technique include the need for two intravenous lines (one for infusion of insulin and glucose, and the other for blood sampling), high-precision glucose measures every 5 minutes, and personnel with expertise to make adjustments in the glucose infusion rate in order to maintain the target level of glycaemia. The participant considerations include the need for two intravenous lines, and the duration of the procedure. Overall, this method is relatively resource-intensive (requiring nursing and investigator time and expertise), and it provides a measurement of insulin sensitivity without a simultaneous measure of β-cell function (as is provided in some methods discussed below).
| Hyperglycaemic clamp-derived insulin sensitivity
The hyperglycaemic clamp technique is discussed in detail below as a method for measurement of β-cell function. This technique also provides an indirect measure of insulin sensitivity, using the rate of glucose disposal under imposed steady-state hyperglycaemic conditions, adjusted for the achieved endogenous insulin (or C-peptide) concentrations. 12, 22 Adjustments are needed for variations in achieved steadystate glucose concentrations, and for urinary glucose losses. Typically, insulin sensitivity is calculated by dividing the glucose disposal rate by the plasma insulin (or C-peptide) concentration at steady state during the last 30 or 60 minutes of a 2-hour hyperglycaemic clamp.
The principal limitation of measuring insulin sensitivity with this method is the dependence of the insulin sensitivity measure on the endogenous late-phase β-cell response. This is primarily an issue where poor late-phase insulin release provides an insufficient stimulus to drive glucose disposal in the face of poor insulin sensitivity, limiting accuracy of measurement of insulin sensitivity.
| Intravenous glucose tolerance test: minimal model-derived insulin sensitivity
The minimal model of glucose kinetics developed by Toffolo et al. 23 and
Bergman et al. 24 allows insulin-mediated glucose disposal to be calculated from intravenous glucose tolerance test (IVGTT) data, with derivations of a model-derived measure of insulin sensitivity (S I ). The minimal model has been extensively evaluated and widely adopted. In a modification of the original methodology, exogenous tolbutamide or (more commonly) insulin is administered after assessing the first-phase insulin response, to better characterize insulin-dependent glucose disappearance where endogenous production is insufficient 25, 26 ; however, in more severe insulin resistance, the standardized exogenous insulin bolus may be insufficient to produce data adequate for modelling.
| Surrogate measures of insulin sensitivity
Indices of insulin sensitivity have been developed using fasting blood samples (eg, inverse fasting insulin, homeostatic model assessment (HOMA), 27 quantitative insulin sensitivity check index (QUICKI), 28 or the combined glucose and insulin excursions of the oral glucose tolerance test (OGTT; eg, the Matsuda index). 19 In cross-sectional evaluations, these fasting and OGTT-derived measures correlate reasonably well with hyperinsulinaemic-euglycaemic clamp or minimal model-derived measures (r = 0.6-0.7). 29 The utility of surrogate indices for longitudinal use has not been extensively evaluated. Some reports have described concurrent changes in multiple indices over time 30, 31 , but, to date, correlations between longitudinal changes in surrogate indices of insulin resistance and more direct measures have only been formally evaluated in one publication. 20 That paper evaluated a cohort of Mexican-American women followed after gestational diabetes, and found changes in the surrogate indices to be less strongly correlated to changes in IVGTTderived S I than is observed in cross-sectional settings.
| MEASURING β-CELL FUNCTION
Glucose is the principal regulator of insulin secretion. It does this via a well-described pathway linking β-cell glucose uptake to changes in ADP/ATP ratios and ultimately to changes in membrane potassium conductance and movement of insulin granules, producing a pulsatile and oscillatory pattern of insulin secretion in health. 32, 33 Non-glucose β-cell stimuli include incretin hormones, acting through a cAMP system to potentiate the response to glucose, 34, 35 and monobasic amino acids, fatty acids, and β-adrenergic agonists, which also act independent of the glucose-sensing systems but converge on the same insulin secretion pathways. 36 These features are exploited in the many methods that have been developed for the measurement of β-cell function. 
| Hyperglycaemic clamp
Under this method, an exogenous glucose infusion is applied to raise blood glucose to a specified target concentration, or to achieve an increment above the individual's fasting glucose. Both the magnitude and timing of the hyperglycaemic stimulus are controlled, allowing a precise and repeatable stimulus to insulin/C-peptide secretion and clear separation of first-and second-phase responses to intravenous glucose ( Figure 2 ).
21,22
The first-phase insulin/C-peptide response primarily consists of release of stored insulin and occurs in the first few minutes after circulating glucose concentrations increase, subsiding within 10 minutes. 38 The first-phase response is measurably diminished in individuals with only modest elevations in fasting glucose and/or IGT, more severely diminished in individuals with fasting glucose concentrations >6.4 mmol/L (115 mg/dL), and absent in T2D.
39-41
The second-phase insulin/C-peptide response begins concurrent with the first-phase response, and consists of a slow and sustained increase in insulin/C-peptide concentrations, reflecting pools of insulin granules with varying kinetic properties. 38, 42, 43 The second-phase response is not lost early in T2D, but declines over time with progressive reduction in β-cell function. 44, 45 The DI can be calculated from data derived from the hyperglycaemic clamp alone, as long as a hyperbolic relationship exists between the measures of insulin/C-peptide secretion and insulin sensitivity. The DI is calculated using the measured insulin/C-peptide response and the indirect measure of insulin sensitivity (M/I), as explained above.
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Examples of application of the hyperglycaemic clamp include understanding the progressive pathophysiology of β-cell dysfunction, 12, 13, 30 and assessing the effects of pharmacological interventions, weight loss and bariatric surgery on β-cell function.
45-47
The ability to measure insulin/C-peptide secretion and insulin sensitivity in a single day is an advantage of the hyperglycaemic clamp. Another advantage is that measures of β-cell function are accurate along the entire spectrum from normal glucose tolerance (Table 1 ).
| Intravenous glucose tolerance test
During the IVGTT, an intravenous bolus of dextrose is given and rapid sampling for measurement of glucose and insulin concentrations is performed during the first 10 minutes of the test to measure the acute (first-phase) insulin and C-peptide responses. Subsequent measurements across the remainder of the test are used to derive the late-(second) phase responses. As noted above, under current usage, a bolus of exogenous insulin is generally applied in order to successfully model insulin sensitivity (S I ).
Investigators have used the IVGTT minimal model to describe progressive loss of β-cell function in the development of diabetes, [48] [49] [50] to describe the physiology of individuals at risk of diabetes, 12, 48, [51] [52] [53] and to follow response to treatment. [54] [55] [56] As with the hyperglycaemic clamp, the IVGTT allows the derivation of measures of β-cell function and insulin sensitivity from a single (Table 1 ).
| Graded glucose infusion
With this method, the insulin/C-peptide response to a prolonged intravenous infusion of glucose is measured. Rather than targeting a particular level of glycaemia, the graded glucose infusion imposes a series of pre-set glucose infusion rates. This produces acute, stepwise increments in blood glucose, engendering stepped insulin secretory responses. [57] [58] [59] The initial bolus generally differs from that used in the hyperglycaemic clamp, and therefore first-phase insulin/Cpeptide response measurements are not directly comparable between hyperglycaemic clamps and graded glucose infusion tests. 60 The graded glucose infusion has been used across the spectrum of glucose tolerance, and has the advantage of allowing derivation of a slope reflecting the β-cell sensitivity to glucose. 59 An indirect measure of insulin sensitivity can be obtained by extending the methodology, using an up-and downgraded glucose procedure, together with minimal modelling. 59 Unless this approach is used, a separate measure of insulin sensitivity is required to calculate a DI. Because of differences in the achieved glucose concentrations, this measurement incorporates degrees of glucose mass action (glucose-mediated glucose disposal) that are different from the other methods; thus, the results are parallel but not strictly similar to other approaches to measure insulin sensitivity. 61 The graded glucose infusion has been used principally in exploring the pathophysiological progression of β-cell dysfunction, 58 and in assessing the effects of treatment interventions on β-cell function. 62 The principal technical limitations of the graded glucose infusion are the need for two intravenous lines, and expertise with the mathematical approaches needed for data extraction. The personnel burden is comparable in terms of time but this method requires less methodological expertise than the hyperglycaemic clamp, and the graded glucose infusion requires less frequent blood sampling overall.
Participant considerations include the need for two intravenous lines,
and a time commitment of 3 to 4 hours ( Table 1 ).
| Glucose-potentiated arginine stimulation test
L-arginine infused as a bolus while the participant is hyperglycaemic at a level of ≥25 mmol/L (450 mg/dL) produces a maximum insulin response considered to reflect the functional secretory capacity of β cells. 36, [63] [64] [65] Individuals with blunted or absent first-phase insulin/Cpeptide response to intravenous glucose maintain a brisk, although reduced response to arginine (Figure 3 ).
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Historically, stimulation with isoproterenol or glucagon was used to measure augmented insulin release, but resulted in unacceptable side effects. 64 Lower variability is observed in the insulin/C-peptide response with arginine vs glucagon; moreover, arginine stimulates glucagon release, allowing a concurrent measure of α-cell function. hyperglycaemic clamp procedure, functionally performing 1 procedure but measuring multiple aspects of β-cell function.
The glucose-potentiated arginine response has been applied in assessing the function of a pancreas or islet cell transplant, 68 and in assessing pharmacological effects on β-cell function in T2D. 69, 70 The principal technical limitations of the glucose-potentiated arginine response are the same as for the hyperglycaemic clamp, with the addition of the clinical supplies needed for the L-arginine infusion.
Participant considerations include the lengthening of the hyperglycaemic clamp procedure, and the fact that~40% of participants experience mild side effects (brief flushing or metallic taste) when Larginine is administered. 66 
| Oral glucose tolerance test
The OGTT can be used to assess β-cell function. The relatively delayed appearance of glucose in the circulation prevents strict separation of first-and second-phase insulin responses; these components are therefore traditionally described as early and late insulin responses. The early response can be evaluated simply as the rise in insulin/C-peptide above basal at any time interval up to 30 minutes after commencing glucose ingestion, or as the "insulinogenic index"
(the increment above basal insulin/C-peptide divided by the increment in glucose in the same time interval). 71 The early insulin response and the insulinogenic index are reduced in IGT and T2D. 72, 73 The late insulin or C-peptide response is generally evaluated as the integrated response over the entire sampled duration; this measure has been less widely used. 45, 72 The use of OGTT varibles to derive a DI is increasingly applied, 8, 73 supported by mathematical evidence for an underlying hyperbolic relationship between specific measures of insulin secretion and insulin sensitivity from the OGTT.
74,75
The OGTT has been widely applied in the evaluation of the pathophysiological progression of β-cell dysfunction, 75, 76 and in assessing the effects of treatment interventions on β-cell function. 77 A core advantage of the OGTT is that it incorporates the physio- 
| Mixed-meal tolerance test
Analogous to the OGTT, a liquid or solid enteral stimulus consisting of a mixture of carbohydrate with other macronutrients can be delivered orally with subsequent sampling of blood glucose and insulin. As with OGTT, this method can be applied to assess contributions of the incretin effect to the overall mixed-meal response. 85 The mixed nutrient load provides a more physiologically relevant comparison to human meal consumption than an isolated glucose load. 86 The same directly calculated and model-derived measures of β-cell responses can be derived from the mixed-meal tolerance test (MMTT) dataset, with parallel advantages and disadvantages. 79, 87, 88 Despite the improved physiological relevance of this method, the delivery of multiple nutrients involved in stimulation of gut hormones and in β-cell as with the OGTT. 9, 13 Differences in size and composition of the enteral load lead to differences in insulin and incretin responses, 86, 89 although there have been recent efforts to standardize the test meal. 9 The MMTT is widely used at present to assess β-cell function in therapeutic trials in type 1 diabetes. In contrast to high variability observed in other populations, results in this population have been highly reproducible. 
| Fasting proinsulin to insulin (or C-peptide) ratio
In people without diabetes, the molar proportion of circulating proinsulin to insulin is~15% in the fasting state. 92, 93 As β-cell failure ensues, processing of proinsulin to insulin and C-peptide is impaired, and the fasting proinsulin to insulin ratio increases 2-to 3-fold in T2D. 92, 93 Interestingly, the ratio is not significantly increased in all individuals with IGT, 94 suggesting that an elevated ratio is an indicator of more established β-cell dysfunction or of increased β-cell demand.
| Homeostatic model assessment
The HOMA method provides estimates of basal β-cell function and insulin sensitivity. 27 Updates to the model take into account variations in hepatic and peripheral glucose resistance, and other wholebody determinants of metabolic physiology. 95 The original linear equations are simplified approximations of the original non-linear solution. 27 With modern computing the direct calculation is widely accessible, particularly with the availability of an online calculator (https://www.dtu.ox.ac.uk/homacalculator/). The use of the online methodology is preferred. 27, 96 Because the model requires only basal glucose and insulin/Cpeptide concentrations, it has obvious advantages in terms of cost and ease of application, and has been widely used in large epidemiological studies, longitudinal cohort studies and clinical trials. HOMA %β is correlated (r = 0.6-0.9) with direct measures of β-cell function in cross-sectional studies of healthy populations with NGT, but may be less reliably related in progressive dysglycaemia and diabetes. 27, 83, 97 Correlations with direct measures are weaker in longitudinal studies, even after accounting for increased variability of the measurements. 20 These surrogate measures have been used primarily in epidemiological studies, although in some instances they have been used to assess treatment effects on β-cell function in pharmacological or surgical studies. 47, 77, 98 These measures have advantages in terms of cost and personnel burden, and require much less of individual participants; however, the compromises entailed make it an imperfect choice for studies primarily assessing β-cell function and response to interventions that may also improve insulin sensitivity.
| CASE STUDY IN METHOD SELECTION: THE RISE APPROACH TO MEASURING β-CELL FUNCTION
The RISE Consortium includes three studies assessing the hypothesis that glucose-lowering will lead to sustained improvement in β-cell function in prediabetes and early T2D 17 :
1. RISE Adult Medication Study: adult participants (aged 20- The optimum selection of methods will be determined by the particular focus of study. Table 1 provides an overview of the main strengths and weaknesses of the methods discussed.
The RISE study is evaluating the effects of interventions, including pharmacotherapeutics and metabolic surgery, on β-cell function, in populations spanning from paediatrics to adults. We elected to measure our β-cell outcomes using a 2-day measurement procedure, namely a 3-hour 75-g OGTT and a 2-stage hyperglycaemic clamp with arginine. This combination of methods provides an assessment of: (1) first-and second-phase insulin/C-peptide responses; (2) insulin sensitivity; (3) maximum β-cell secretory capacity; and (4) early and late insulin response to an enteral glucose stimulus. This protocol has been successfully implemented in a multicentre consortium, highlighting the feasibility of using these methods in treatment studies with multiple participating study sites.
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